Degeneration of human photosensitive retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson’s disease

Please use this identifier to cite or link to this item: http://hdl.handle.net/10045/79768
Información del item - Informació de l'item - Item information
Title: Degeneration of human photosensitive retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson’s disease
Authors: Ortuño Lizarán, Isabel | Esquiva Sobrino, Gema | Beach, Thomas G. | Serrano, Geidy | Adler, Charles H. | Lax, Pedro | Cuenca, Nicolás
Research Group/s: Neurobiología del Sistema Visual y Terapia de Enfermedades Neurodegenerativas (NEUROVIS)
Center, Department or Service: Universidad de Alicante. Departamento de Fisiología, Genética y Microbiología
Keywords: Retina | Parkinson’s disease | Circadian rhythms | Sleep disorders | Melanopsin retinal ganglion cell | Human
Knowledge Area: Fisiología | Biología Celular
Issue Date: 10-Sep-2018
Publisher: BioMed Central
Citation: Acta Neuropathologica Communications. 2018, 6:90. doi:10.1186/s40478-018-0596-z
Abstract: Parkinson’s disease (PD) patients often suffer from non-motor symptoms like sleep dysregulation, mood disturbances or circadian rhythms dysfunction. The melanopsin-containing retinal ganglion cells are involved in the control and regulation of these processes and may be affected in PD, as other retinal and visual implications have been described in the disease. Number and morphology of human melanopsin-containing retinal ganglion cells were evaluated by immunohistochemistry in eyes from donors with PD or control. The Sholl number of intersections, the number of branches, and the number of terminals from the Sholl analysis were significantly reduced in PD melanopsin ganglion cells. Also, the density of these cells significantly decreased in PD compared to controls. Degeneration and impairment of the retinal melanopsin system may affect to sleep and circadian dysfunction reported in PD pathology, and its protection or stimulation may lead to better disease prospect and global quality of life of patients.
Sponsor: This work was supported by the Michael J. Fox Foundation for Parkinson’s Research. I.O.L. acknowledges financial support from the Ministerio de Educación, Spain (FPU 14/03166). N.C. acknowledges financial support from the Ministerio de Economía y Competitividad, Spain (MINECO-FEDER-BFU2015-67139-R), Generalitat Valenciana (Prometeo 2016/158), and Instituto Carlos III (ISCIII RETICS-FEDER RD16/0008/0016). The Brain and Body Donation Program has been supported by the National Institute of Neurological Disorders and Stroke (U24 NS072026), the National Institute on Aging (P30 AG19610), the Arizona Department of Health Services, the Arizona Biomedical Research Commission, and the Michael J. Fox Foundation for Parkinson’s Research.
URI: http://hdl.handle.net/10045/79768
ISSN: 2051-5960
DOI: 10.1186/s40478-018-0596-z
Language: eng
Type: info:eu-repo/semantics/article
Rights: © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Peer Review: si
Publisher version: https://doi.org/10.1186/s40478-018-0596-z
Appears in Collections:INV - NEUROVIS - Artículos de Revistas

Files in This Item:
Files in This Item:
File Description SizeFormat 
Thumbnail2018_Ortuno-Lizaran_etal_ActaNeuropathComm.pdf3,39 MBAdobe PDFOpen Preview


This item is licensed under a Creative Commons License Creative Commons